A kill code is embedded in every cell in the body whose function may be to cause the self-destruction of cells that become cancerous, reports a new Northwestern Medicine study.
A drug called bevacizumab added to adjuvant chemotherapy did not improve outcomes for patients with a form of high-risk breast cancer, according to a study published in the Journal of Clinical Oncology.
Understanding environmental factors helps scientists like cancer epidemiologist Lifang Hou, MD, PhD, chief of Cancer Epidemiology and Prevention in the Department of Preventive Medicine, detect the disease earlier.
Northwestern Medicine scientists have discovered how circulating tumor cells cluster together during metastasis — findings that reveal a novel mechanism for how cancer spreads and a potential new target for treatment.
A drug called palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer.
Targeting cancer cells with a transcription elongation inhibitor delayed tumor progression in animal models, according to a recent Northwestern Medicine study.
In a recent clinical trial, a drug called apalutamide added to standard therapy slowed cancer progression in men with prostate cancer, while maintaining quality of life.
Northwestern Medicine investigators are leading a Specialized Program of Research Excellence (SPORE) in brain cancer with a special emphasis on glioblastoma.
A new study has identified genes that, when inhibited, may slow or stop the progression of primary effusion lymphoma.
Faculty, family and friends gathered at a symposium to honor Robert Goldman, PhD, chair of Cell and Molecular Biology, and his distinguished scientific career.